Research Projects & Grants

For Profit Organization

• A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD), Role: Investigator, NGM Biopharmaceuticals, Inc., (10/2022 - 10/2023) Status: Completed
• A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of Brolucizumab 6 mg compared to Aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON), Role: Investigator, Novartis Pharmaceuticals Corporation, (08/2022 - 08/2023) Status: Completed
• A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema, Role: Investigator, Unity Biotechnology, Inc., (06/2022 - 06/2023) Status: Completed

Internal

• Endophthalmitis risk without postoperative topical antibiotics after retina surgery, Role: PI, LLU Dept. of Ophthalmology, (05/2024) Status: Approved